AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

World Dry Eye Medication Market Report 2020: Major Players are Novartis, Allergan, Otsuka, Santen Pharmaceutical and Auven Therapeutics - ResearchAndMarkets.com

November 13, 2019

DUBLIN--(BUSINESS WIRE)--Nov 13, 2019--

The “Dry Eye Medication Global Market Report 2020” report has been added to ResearchAndMarkets.com’s offering.

The increased number of cases for dry eye disease results in the increased demand for its treatment. Factors such as aging, lack of vitamin A, wearing lenses, eye surgeries, direct contact with dry wind or smoke, and exposing one’s eyes to screens for long duration increase the occurrence of the dry eye more likely. For example, a survey conducted by the American Academy of Ophthalmology in 2015 reported that in the USA, nearly 3.2 million women and 1.68 million men, over the age of 50 were affected by dry eye syndrome. Similarly, a 2017 study conducted by Indian Journal Ophthalmology indicated a 32% prevalence of dry eye disease in the Northern part of India. Rising prevalence of the disease would increase the demand for its treatment and ultimately facilitate the growth of this market.

The market for dry eye medication is restricted by the long approval process that is undertaken before any drug is approved by the concerned authority. The standard protocol for testing any new drug demands a series of tests and trials including laboratory tests, animal model tests, and clinical trials. Most drugs fail during clinical trials and only a small percent of them successfully move forward. The cumbersome process of obtaining approvals takes longer duration of time and restricts the growth of this market. For example, Xiidra, a drug for dry eyes was approved by FDA in 2016 after its safety and effectiveness were assessed on more than 1,000 adults in four different clinical trials. Similarly, Kissei Pharmaceutical announced to discontinue the development of KCT-0809 drug after it failed to pass the 3rd phase of clinical trials in 2017.

Treatment for dry eye disease improved with incorporation of modern techniques that helped invent advanced hyaluronic acid-based lubricants and lipid emulsions. This technology replaces artificial tears that include isotonic sodium chloride and provide long-lasting lubrication on the surface of the eye. For instance, in 2018 Allergan, a global pharmaceutical company, launched Refresh Repair Lubricant Eye Drops which are designed to repair and protect the eyes from dry eye disease and improve the clarity of vision and is formulated with carboxymethylcellulose (CMC), hyaluronic acid, and osmoprotectants. These components maintain the health of the ocular surface and safeguard epithelial cells. Advances in technology will have a positive effect on the market.

The dry eye medication market is strictly regulated by government agencies such USFDA (Food and Drug Administration), European Medicines Agency (EMA), and others. For instance, in the USA, FDA evaluates and approves the drugs meant for dry eye treatment. According to Section 201(g) of the FDA and CFR (Code of federal regulations) act, the licenses are granted to the drug manufacturing companies allowing them to sell only those drugs that are safe and clinically effective. FDA demands a number of tests and several clinical trial rounds before granting such approvals. For example, in January 2019, FDA approved Kala Pharmaceuticals eye related drug called INVELTYS.

In 2019, Takeda, largest pharmaceutical in Asia acquired the Shire plc for $62 billion. This acquisition expands Takeda’s portfolio which is strengthened by innovative drugs to different therapeutics including dry eyes and has expanded the geographic footprint of the company in Japan and the USA. Shire was founded in 1986 and is headquartered in Massachusetts, USA. Shire develops medicines that aim to improve their patient’s quality of life.

Key Topics Covered

1. Executive Summary

2. Dry Eye Medication Market Characteristics

3. Dry Eye Medication Market Size And Growth

3.1. Global Dry Eye Medication Historic Market, 2015 - 2019, $ Billion

3.1.1. Drivers Of The Market

3.1.2. Restraints On The Market

3.2. Global Dry Eye Medication Forecast Market, 2019 - 2022F, 2025F, 2030F, $ Billion

3.2.1. Drivers Of The Market

3.2.2. Restraints On the Market

4. Dry Eye Medication Market Segmentation

4.1. Global Dry Eye Medication Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

4.2. Global Dry Eye Medication Market, Segmentation By end-user, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

4.3. Global Dry Eye Medication Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

5. Dry Eye Medication Market Regional & Country Analysis

5.1. Global Dry Eye Medication Market, Split By Region, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

5.2. Global Dry Eye Medication Market, Split By Country, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

Companies Profiled

Companies Mentioned (A-Z)

For more information about this report visit https://www.researchandmarkets.com/r/92d1l1

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191113005325/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/13/2019 04:50 AM/DISC: 11/13/2019 04:50 AM

http://www.businesswire.com/news/home/20191113005325/en